Complications of foam sclerotherapy

Phlebology

Volumn 27, Issue SUPPL. 1, 2012, Pages 46-51

  Cavezzi, A ^a,b   Parsi, K ^c,d  

^a Vascular Unit   (Italy)

^b Clinica Stella Maris   (Italy)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anaphylaxis; Complications; Foam sclerotherapy; Skin necrosis; Stroke; Telangiectatic matting; Thrombosis

Indexed keywords

ADRENALIN; ANTITHROMBOCYTIC AGENT; ENDOTHELIN 1; HEMOSIDERIN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN; VASODILATOR AGENT;

ALLERGIC REACTION; CLINICAL FEATURE; COMPLICATION; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; EDEMA; EXTRAVASATION; FOAM; FOAM SCLEROTHERAPY; GAS EMBOLISM; HUMAN; HYPERPIGMENTATION; INJECTION SITE NERVE DAMAGE; LUNG EMBOLISM; MIGRAINE; NEUROLOGICAL COMPLICATION; OXYGEN THERAPY; PATENT FORAMEN OVALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SAPHENOUS VEIN; SCAR FORMATION; SCLEROTHERAPY; SEROTONIN BLOOD LEVEL; SKIN BRUISING; SKIN IRRITATION; SKIN MANIFESTATION; STROKE; SUPERFICIAL VEIN THROMBOSIS; TELANGIECTATIC MATTING; TISSUE NECROSIS; TRANSIENT ISCHEMIC ATTACK; URTICARIA; VALSALVA MANEUVER; VASOSPASM; VEIN THROMBOSIS; VENO ARTERIOLAR REFLEX VASOSPASM; VISUAL DISORDER;

ANAPHYLAXIS; EDEMA; FORAMEN OVALE, PATENT; HUMANS; NECROSIS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; STROKE; VENOUS THROMBOSIS;

EID: 84856786768     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2012.012S09     Document Type: Review

References (30)

1. Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004;30:694-703; discussion 10.1111/j.1524-4725.2004.30208. x
2. Thibault P. Sclerotherapy and ultrasound-guided sclerotherapy. In: Bergan JJ, ed. The Vein Book. Burlington, MA, USA: Academic Press, 2006: 189-200
3. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg 2002;28:11-5
4. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:123-8; discussion 8
5. Parsi K. Paradoxical embolism, stroke and sclerotherapy. Phlebol/Venous Forum R Soc Med 2011. 10.1258/phleb.2011.010098
6. Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007;33:116-21
7. Gillet JL, Guedes JM, Guex JJ, et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients. Phlebol/Venous Forum R Soc Med 2009;24:131-8
8. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with sclerosant foam. J Cardiovasc Surg 2006;47:9-18
9. Myers KA, Jolley D. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg 2008;36:602-5
10. Guex JJ. Complications of sclerotherapy: an update. Dermatol Surg 2010;36(Suppl 2):1056-63
11. Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007;94:925-36
12. Gillet JL, Donnet A, Lausecker M, Guedes JM, Guex JJ, Lehmann P. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebol/Venous Forum R Soc Med 2010;25:261-6
13. Parsi K, Pilotelle A, Connor DE, Low J, Ma DDF, Joseph JE. Low concentration detergent sclerosants induce platelet activation and microparticle release but inhibit aggregation in vitro. The XIII Annual Scientific Meeting and Workshops of The Australian College of Phlebology. Melbourne, Australia, 2011, 57
14. Frullini A, Felice F, Burchielli S, Di Stefano R. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebol/Venous Forum R Soc Med 2011;26:203-8
15. Morrison N, Neuhardt DL, Rogers CR, et al. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008;47:830-6
16. Ma RW, Pilotelle A, Paraskevas P, Parsi K. Three cases of stroke following peripheral venous interventions. Phlebol/Venous Forum R Soc Med 2011;26:280-4
17. Parsi K. Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications. Phlebol/Venous Forum R Soc Med 2011;26:140-7
18. Morrison N. In: Bergan J, Cheng V, eds. Studies on Safety of Foam Sclerotherapy. In Foam Sclerotherapy: A Textbook. London: Royal Society of Medicine Press, 2008
19. Parsi K, Exner T, Connor DE, Herbert A, Ma DD, Joseph JE. The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg 2008;36:216-23
20. Wright D, Rush J, Butler B. Polidocanol does not remain on the surface of bubbles free in the venous blood. Int Angiol 2009;4(Suppl 1):39
21. Schuller-Petrovic S, Pavlovic MD, Neuhold N, Brunner F, Wolkart G. Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy. J Eur Acad Dermatol Venereol: JEADV 2011;25:983-6
22. Grommes J, Franzen EL, Binnebosel M, et al. Inadvertent arterial injection using catheter-assisted sclerotherapy resulting in amputation. Dermatol Surg 2011;37:536-8
23. Parsi K, Partsch H, Rabe E, Ramelet AA. Reticulate eruptions. Part 1: Vascular networks and physiology. Australas J Dermatol. 2011;52:159-66
24. Parsi K, Partsch H, Rabe E, Ramelet AA. Reticulate eruptions: Part 2. Historical perspectives, morphology, terminology and classification. Australas J Dermatol. 2011;52:237-44
25. Bihari I, Magyar E. Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg 2001;27:133-6
26. Cavezzi A, Frullini A, Ricci S, Tessari L. Treatment of varicose veins by foam sclerotherapy. Phlebology/ Venous Forum R Soc Med 2002;17:13-8
27. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg 1995;21:19-29; quiz 31-2
28. Palm MD, Guiha IC, Goldman MP. Foam sclerotherapy for reticular veins and nontruncal varicose veins of the legs: a retrospective review of outcomes and adverse effects. Dermatol Surg 2010;36(Suppl 2):1026-33
29. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg 2004;30:367-72; discussion 72
30. Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg 2005;31:631-5; discussion 5